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Background. Postmortem minimally invasive tissue sampling (MITS) is a potential alternative to the gold standard complete 
diagnostic autopsy for identifying specific causes of childhood deaths. We investigated the utility of MITS, interpreted with available 
clinical data, for attributing underlying and immediate causes of neonatal deaths.
Methods. This prospective, observational pilot study enrolled neonatal deaths at Chris Hani Baragwanath Academic Hospital 
in Soweto, South Africa. The MITS included needle core-biopsy sampling for histopathology of brain, lung, and liver tissue. 
Microbiological culture and/or molecular tests were performed on lung, liver, blood, cerebrospinal fluid, and stool samples. The “un-
derlying” and “immediate” causes of death (CoD) were determined for each case by an international panel of 12–15 medical specialists.
Results. We enrolled 153 neonatal deaths, 106 aged 3–28 days. Leading underlying CoD included “complications of prematurity” 
(52.9%), “complications of intrapartum events” (15.0%), “congenital malformations” (13.1%), and “infection related” (9.8%). Overall, in-
fections were the immediate or underlying CoD in 57.5% (n = 88) of all neonatal deaths, including the immediate CoD in 70.4% (58/81) 
of neonates with “complications of prematurity” as the underlying cause. Overall, 74.4% of 90 infection-related deaths were hospital ac-
quired, mainly due to multidrug-resistant Acinetobacter baumannii (52.2%), Klebsiella pneumoniae (22.4%), and Staphylococcus aureus 
(20.9%). Streptococcus agalactiae was the most common pathogen (5/15 [33.3%]) among deaths with “infections” as the underlying cause.
Conclusions. MITS has potential to address the knowledge gap on specific causes of neonatal mortality. In our setting, this 
included the hitherto underrecognized dominant role of hospital-acquired multidrug-resistant bacterial infections as the leading 
immediate cause of neonatal deaths.
Keywords. MITS;  immediate cause of death; underlying cause of death; hospital acquired infection;  core biopsy.
In 2017, 47% of an estimated 5.4 million deaths in children 
aged <5  years occurred within 1  month of birth, with more 
than three-quarters (77%) occurring in sub-Saharan Africa and 
South Asia [1]. Currently, causes of under-5 childhood deaths 
in low- and middle-income countries (LMICs) are mainly in-
ferred from vital registration and limited verbal autopsy data. 
In 2015, only 3% of under-5 childhood cause-specific mortality 
fractions (CSMFs) were based on adequate vital registration 
data, primarily from high-income countries [2]. Inadequacy 
of vital registration data, coupled with verbal autopsies being 
available for as few as 1 of every 850 deaths in most LMICs [3], 
necessitates modeling simulations to impute childhood CSMFs. 
Furthermore, although verbal autopsies have high concord-
ance in attributing cause of death (CoD) diagnosis compared 
to physician diagnosis in high-quality hospitals [4], this is only 
achievable at a broad syndromic level. Also, CSMF is analyzed 
for the underlying medical condition that led to death, which 
could undermine recognition of more immediate medical 
events resulting in death that might be preventable or treatable.
Limitations in identifying the contributory role of infectious 
causes of deaths is accentuated by scarcity and challenges in 
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antemortem and postmortem investigation of children dying 
in LMICs [5]. Complete diagnostic autopsy (CDA) is the gold 
standard for CoD attribution; however, limited pathology ca-
pacity, resource constraints, and cultural and religious belief 
barriers are impediments to undertaking CDA in LMICs [5]. 
Nevertheless, more refined methods than verbal autopsies are 
required to elucidate the CoD, which could identify preventable 
causes and guide empiric treatment [2, 6]. The potential of min-
imally invasive tissue sampling (MITS) is one such option [7, 
8] and is theoretically acceptable (73%) even in LMIC settings 
[8]. A recent pilot validation study from Mozambique reported 
moderate concordance between CDA and MITS in 41 neo-
natal deaths (κ = 0.40 [95% confidence interval, .18–.63), albeit 
without considering clinical information when attributing the 
CoD using the MITS data. The concordance between CDA and 
MITS was higher for deaths attributed to “infections” (85%) or 
“preterm complications” (60%), while expectedly lower for con-
genital abnormalities (40%) [9].
The Bill & Melinda Gates Foundation (BMGF) is funding 
the multicountry Child Health and Mortality Prevention 
Surveillance (CHAMPS) network, focused on using MITS 
to ascertain and track the CoD in children in high-mortality 
areas [6]. As a prelude to the CHAMPS program, we piloted the 
utility of MITS, interpreted together with available antemortem 
clinical and laboratory information, to ascertain the causes of 
stillbirth, neonatal, and childhood deaths in an LMIC setting.
In this manuscript, we report on the utility of MITS for at-
tributing the underlying and/or immediate CoD among neo-
nates in Soweto, South Africa.
METHODS
Detailed characteristics of the study population, study site, 
the MITS procedure, laboratory assays, and CoD attribu-
tion are provided in the Supplementary Materials, and briefly 
described here.
Study Site and Population, Study Design, and Procedures
This prospective, observational pilot study was undertaken at 
Chris Hani Baragwanath Academic Hospital (CHBAH), the 
only public hospital in Soweto during the study period (16 
July 2015–30 July 2016). Public healthcare is provided free-
of-service fee by the State to all pregnant women and children 
<6  years of age. Although South Africa is a middle-income 
country, the estimated neonatal mortality rate for Soweto was 
22 per 1000 live births (MatFlu Cohort, unpublished data).
Deaths occurring in the neonatal and pediatric medical 
wards were identified by study staff through reporting by the 
attending physicians and review of the inpatient ward and mor-
tuary registries throughout the study period, except from 18 
December 2015 to 3 January 2016. Also included in the study 
were children who were dead upon arrival at the hospital. 
Following identification of the death, study staff approached 
bereaved parents/guardians to provide grief counseling and in-
quire about their interest regarding study participation. Parents 
were provided an opportunity to consult with other family 
members, including their elders. Study inclusion criteria in-
cluded birth weight >750 g, residence in Soweto, feasibility of 
undertaking the MITS within 36 hours after death, and parental 
consent for participation.
Minimally Invasive Tissue Sampling
The MITS procedures were undertaken by trained study staff. 
After the body surface was washed with water and decontam-
inated using 70% alcohol, multiple brain, lung, and liver tissue 
samples were collected using core biopsy needles. The tissue 
samples were sent for histopathological examination (all), cul-
ture (lung and liver), and molecular tests (lung). Furthermore, 
blood and cerebrospinal fluid (CSF) samples were collected for 
microbiological culture and molecular testing, and rectal swabs 
for molecular testing. Human immunodeficiency virus (HIV) 
polymerase chain reaction (PCR) testing (Roche COBAS® 
TaqMan HIV-1 Qualitative Test Version 2, Roche Molecular 
Systems, Branchburg, New Jersey) was performed on whole 
blood samples at the National Health Laboratory Service 
(NHLS) (Supplementary Table 1).
Blood culture using the BacT/Alert microbial system 
(bioMérieux, Marcy l’Etoile, France), lung and CSF microbial cul-
ture, and antibiotic susceptibility testing were undertaken at NHLS.
All molecular tests were undertaken at the Respiratory and 
Meningeal Pathogens Research Unit laboratory using commer-
cially available multiplex Fast-Track Diagnostics (FTD, Sliema, 
Malta) PCR assays, as detailed in the Supplementary Materials.
Histopathological Diagnosis
Two sets of organ tissue samples were collected from each site; 
1 set was processed locally at the NHLS and the other at the 
Centers for Disease Control and Prevention (CDC) in Atlanta, 
Georgia. Hematoxylin and eosin (H&E) stains were done and 
selected specific stains including Ziehl-Neelsen for mycobac-
teria, Grocott methenamine silver and periodic acid-Schiff for 
fungi, and Gram stain for bacteria as indicated by the histolog-
ical findings. Immunohistochemistry was also performed with 
the choice of antibody guided by the H&E findings, molecular 
results, and microbiological findings [10].
Determination of CoD
The CoD was determined by an international panel constituting 
pathologists, pediatricians, epidemiologists, microbiologists, an 
obstetrician, infectious disease specialists, and international 
coding and certification experts (listed under the Determination 
of Cause of Death [DeCoDe] panel, see Acknowledgments). The 
DeCoDe panel reviewed clinical, antemortem, and postmortem 
data to make a CoD determination, which was recorded using 
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a modified standard reporting template (Supplementary Table 
2) based on the World Health Organization’s International 
Classification of Diseases, Tenth Revision (ICD-10) for deaths 
during the perinatal period [11]. This included recording the 
“underlying condition” associated with initiating the chain of 
events leading or predisposing to death, subsequent antecedent 
medical conditions, and the final or “immediate” condition 
which resulted in death. The DeCoDe panel scored the level of 
certainty on CoD attribution for the “immediate” and “under-
lying” causes as level 1 (confident), level 2 (probable), and level 
3 (uncertain but possible). The final CoD forms were ICD-10 
coded by a medical doctor (F. S.).
Statistical Analysis
We stratified cases into early neonatal death (<72 hours; END) 
and late neonatal death (3–27 days; LND). For all variables, we 
calculated descriptive statistics and provided medians with in-
terquartile range (IQR) for continuous variables and propor-
tions for categorical variables. For select variables, differences 
between the END and LND were tested using χ 2 or Fisher 
exact test, with a P value ≤.05 considered significant. Statistical 
analysis was done using Stata software version 15 (StataCorp, 
College Station, Texas).
Ethical Considerations
This study was approved by the Human Research Ethics 
Committee (reference number 150215)  of the University of 
the Witwatersrand. Parental consent was obtained prior to any 
MITS procedure. Post-MITS, the study team continued to pro-
vide grief counseling.
RESULTS
Of 236 neonatal deaths eligible for enrollment and whose parents 
were approached for study participation, 153 (65.7%) consented. 
Additional results are provided in the Supplementary Materials. 
There were 47 ENDs and 106 LNDs (Supplementary Figure 1). 
Thirty-five percent (n  =  51) of neonates who died were born 
to HIV-infected women, including 41.5% (17/41) of ENDs and 
32.5% (34/105) of LNDs (Table 1). Only 2 (1.3%) of the HIV-
exposed neonates acquired HIV from the mother, diagnosed by 
HIV PCR. Eighty percent of cases weighed <2500 g at birth, and 
78.6% were born prematurely (Table 1). The median ages on ad-
mission were 1 day and 9 days for END and LND, respectively. All 
of the END and 90 of the LND cases had never been discharged 
from hospital since birth. The median duration of hospitaliza-
tion before death of the remaining 16 LNDs was 11 days (range, 
3–26 days). The median time between death and undertaking the 
MITS was 23.4 hours (IQR, 14–37 hours) (Table 1). The majority 
(76.8%) of neonatal deaths with MITS had adequate core samples 
for histological examination, with 8.4% suboptimal samples and 
only 0.6% autolyzed (Supplementary Table 3).
Underlying CoD Attribution
The DeCoDe panel assigned an underlying and/or immediate 
CoD for all cases, except 1 tenuously attributed to “sepsis” at 
level 3 certainty. The most common underlying CoD categories 
were “low birth weight [LBW]/prematurity complications” 
(81/153 [52.9%]), “complications of intrapartum events” 
(23/153 [15.0%]), “congenital malformations” (20/153 [13.1%]), 
and “infection related” (15/153 [9.8%]) (Table 2). “LBW/pre-
maturity complications” was more common as an underlying 
Table 1.  Demographic and Clinical Features of Early (<72 Hours) and Late (3–27 Days) Neonatal Deaths Investigated by Minimally Invasive Tissue 
Sampling
Features Total (N = 153) END (n = 47) LND (n = 106)
Median (IQR) age, d, on admission 5.0 (2–11) 1.0 (0–2) 9.0 (5–14)
Male sex, No. (%) 76 (49.7) 23 (48.9) 53 (50.0)
HIV exposed 51/146 (34.9) 17/41 (41.5) 34/105 (32.4)
HIV PCR reactivea 2/149 (1.3) 1/47 (2.1) 1/102 (1.0)
Median (IQR) weight on admission, g 1280 (943–2410) 1485 (960–2490) 1250 (930–2395)
 LBW (<2500–1500 g) 34/152 (22.4) 10/47 (21.3) 24/105 (22.9)
 Very LBW (<1000–1499 g) 36/152 (23.7) 8/47 (17.0) 28/105 (26.7)
 Extremely LBW (<1000 g) 51/152 (33.6) 16/47 (34.0) 35/105 (33.3)
Median (IQR) gestational age, wk 30.0 (27–36) 31 (27–37) 30 (27–35)
 34 to <37 wk GA 17/140 (12.1) 5/45 (11.1) 12/95 (12.6)
 28 to <34 wk GA 53/140 (37.9) 15/45 (34.1) 38/95 (39.6)
 <28 wk GA 40/140 (28.6) 12/45 (26.7) 28/95 (29.5)
Significant congenital abnormalitiesb 12/114 (10.5) 4/31 (12.9) 8/83 (9.6)
Median (IQR) No. of days between admission and death 4.0 (2.0–9.0) 1.0 (0.0–2.0) 7.0 (4.0–13.0)
Median (IQR) time between death and MITS, h 23.4 (14.3–37.3) 21.6 (14.4–1.7) 24.7 (13.5–38.9)
Data are presented as no./No. (%) unless otherwise indicated.
Abbreviations: END, early neonatal death; GA, gestational age; HIV, human immunodeficiency virus; IQR, interquartile range; LBW, low birth weight; LND, late neonatal death; MITS, mini-
mally invasive tissue sampling; PCR, polymerase chain reaction.
aHIV PCR test done on postmortem sample. 
bSignificant congenital abnormalities recorded in medical notes among END were 1 each of anencephaly, hydrocephalus, microcephaly, and unspecified dysmorphism; and in LND 1 each 
of patent ductus arteriosus, atrial septal defect, and tracheoesophageal fistula, as well as 2 hydrops fetalis and 3 exomphalos cases. 
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Table 2. Underlying Cause of Death Categories and Specific Immediate Cause of Death Attribution of Early (<72 Hours) and Late (3–28 Days) Neonatal 
Deaths by the Determination of Causes of Death Panel
Underlying and Specific Immediate Cause of Death
Total  
(N = 153)
Early Neonatal Death 
(n = 47)
Late Neonatal Death  
(n = 106) P Valuea
Low birth weight/prematurity complications (N9)a,b n = 81 (52.9) n = 18 (38.3) n = 63 (59.4) .022
 Sepsis (all)c 30 (37.0) 4 (22.2) 26 (41.3)  
 Nosocomial sepsisc 26 (32.1) 2 (11.1) 24 (38.1)  
 Pneumonia (all) 23 (28.4) 2 (11.1) 21 (33.3)  
 Nosocomial pneumonia 21 (25.9) 1 (5.6) 20 (31.7)  
 Pulmonary mucormycosis 1 (1.2) 0 (0.0) 1 (1.6)  
 Meningitis (nosocomial)d 4 (4.9) 0 (0.0) 4 (6.3)  
 Birth asphyxiae 1 (1.2) 1 (5.6) 0 (0.0)  
 Hyaline membrane diseasef 14 (17.3) 9 (50.0) 5 (7.9)  
 Pneumothorax 1 (1.2) 1 (5.6) 0 (0.0)  
 Pulmonary hemorrhage 1 (1.2) 0 (0.0) 1 (1.6)  
 Intraventricular hemorrhage 4 (4.9) 1 (5.6) 3 (4.8)  
 Necrotizing enterocolitis 1 (1.2) 0 (0.0) 1 (1.6)  
 Hypoxic ischemic encephalopathy 1 (1.2) 0 (0.0) 1 (1.6)  
Complications of intrapartum events (N4)a n = 23 (15.0) n = 16 (34.0) n = 7 (6.6) < .001
 Sepsis 1 (4.3) 1 (6.3) 0 (0.0)  
 Nosocomial pneumonia 1 (4.3) 0 (0.0) 1 (14.3)  
 Intrauterine hypoxia 4 (17.4) 4 (25.0) 0 (0.0)  
 Birth asphyxia 1 (4.3) 0 (0.0) 1 (14.3)  
 Hypoxic ischemic encephalopathyg 16 (69.6) 11 (68.8) 5 (71.4)  
Congenital malformations, deformations,  
and chromosomal disorder (N1)a
n = 20 (13.1) n = 8 (17.0) n = 12 (11.3) .44
 Sepsis (all) 5 (25.0) 1 (12.5) 4 (33.3)  
 Nosocomial sepsis 4 (20.0) 0 (0.0) 4 (33.3)  
 Pneumonia (all) 4 (20.0) 0 (0.0) 4 (33.3)  
 Nosocomial pneumonia 2 (10.0) 0 (0.0) 2 (16.7)  
 Vascular disorder of intestines 1 (5.0) 0 (0.0) 1 (8.3)  
 Acute kidney failure 1 (5.0) 0 (0.0) 1 (8.3)  
 Birth asphyxia 1 (5.0) 1 (12.5) 0 (0.0)  
 Persistent fetal circulation 1 (5.0) 1 (12.5) 0 (0.0)  
 Congenital malformationsh 7 (35.0) 5 (62.5) 2 (16.7)  
Infection (N6)a,i n = 15 (9.8) n = 4 (8.5) n = 11 (10.4) .99
 Sepsis (all) 6 (40.0) 2 (50.0) 4 (36.4)  
 Nosocomial sepsis 2 (13.3) 0 (0.0) 2 (18.2)  
 Pneumonia (all)j 3 (20.0) 0 (0.0) 3 (27.3)  
 Nosocomial pneumonia 2 (13.3) 0 (0.0) 2 (18.2)  
 Meningitis 3 (20.0) 0 (0.0) 3 (30.0)  
 Intrauterine hypoxia 2 (13.3) 2 (50.0) 0 (0.0)  
 Acquired hydrocephalus 1 (6.7) 0 (0.0) 1 (9.1)  
Respiratory and cardiovascular disorders (N7)a n = 5 (3.3) n = 1 (2.1) n = 4 (3.8) .99
 Nosocomial pneumonia 1 (20) 0 (0.0) 1 (25.0)  
 Nosocomial meningitisk 1 (20) 0 (0.0) 1 (25.0)  
 Persistent fetal circulationl 3 (60.0) 1 (100) 2 (50.0)  
Convulsions and disorders of cerebral status (N5)a n = 1 (0.7) n = 0 n = 1 (0.9) .99
 Nosocomial pneumoniam 1 (100) 0 (0.0) 1 (100)  
Other neonatal conditions (N8)a n = 7 (4.6) n = 0 n = 7 (6.6) .10
 Subarachnoid hemorrhage 1 (14.3) 0 (0.0) 1 (14.3)  
 Candidiasis 1 (14.3) 0 (0.0) 1 (14.3)  
 Kernicterus due to isoimmunization 3 (42.9) 0 (0.0) 3 (42.9)  
 Necrotizing enterocolitis 1 (14.3) 0 (0.0) 1 (14.3)  
 Hypoxic ischemic encephalopathy 1 (14.3) 0 (0.0) 1 (14.3)  
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cause in LND (63/106 [59.4%]) than END (18/47 [38.3%]; 
P =  .022), whereas “complications of intrapartum events” was 
more common in END than in LND (16/47 [34.0%] vs 7/106 
[6.6%]; P < .001; Table 2).
Overall, the DeCoDe panel scored their diagnoses on the un-
derlying CoD as level 1, level 2, and level 3 certainty in 88.2%, 
9.8%, and 2% of cases, respectively (Supplementary Table 4A). 
Similarly, there was a high level of confidence in attributing an 
immediate CoD (89.5%), whereas 9.2% and 1.3% of the imme-
diate CoD diagnoses were considered as level 2 or level 3, re-
spectively (Supplementary Table 4B).
Immediate CoD in Cases With an Underlying Diagnosis of LBW/Prematurity 
Complications
Among deaths attributed to “LBW/prematurity complications” 
as the underlying cause, infections were the immediate CoD 
in 70.4% (58/81) of cases; more commonly so in LND (52/63 
[82.5%]) than among END (6/18 [33.3%]; P <  .001) (Table 2). 
The specific infection-related diagnoses included sepsis (30/81 
[37.0%]), pneumonia (23/81 [28.4%]), and meningitis (4/81 
[4.9%]), of which 86.7% (26/30), 91.3% (21/23), and 100% (4/4), 
respectively, were hospital acquired. Hospital-acquired sepsis, 
pneumonia, and meningitis were more common as an imme-
diate CoD among LND (48/63 [76.2%]) than END (3/18 [16.6%]; 
P < .001) in cases with “LBW/prematurity complications” as the 
underlying cause. Histologically confirmed hyaline membrane 
disease was more common as the immediate cause among ENDs 
(9/18 [50.0%]) than LNDs (5/63 [7.9%]) (P < .001).
Immediate CoD in Cases With Underlying Diagnoses Other Than LBW/
Prematurity Complications
Among deaths attributed to “congenital malformations” as the 
underlying cause, infections were the dominant (9/20 [45%]) 
immediate CoD, two-thirds of which were hospital acquired, 
whereas 35% (7/20) of these deaths were a direct consequence 
of the underlying congenital abnormality (Table 2).
Deaths attributed to “complications of intrapartum events” 
were mainly due to hypoxic brain damage, 71.4% (15/21) of 
which were END cases. Hypoxic brain injury was also attributed 
as an immediate CoD in neonates with underlying causes other 
than “complications of intrapartum events,” with an overall prev-
alence of 17.0% (26/153); and more commonly so among END 
(18/47 [38.3%]) than LND (8/106 [7.5%]) (P < .001; Table 2).
Infectious Diseases as an Underlying or Immediate CoD
Overall, community-associated infections were the underlying 
and/or immediate CoD in 15.0% (23/153) of cases, including 
sepsis (9.2%), pneumonia (5.9%), and meningitis (2.0%) 
(Table 3). The leading pathogens identified among the 23 
community-associated infection–related deaths included group 
B Streptococcus (GBS) (n = 5 [21.7%]), Escherichia coli (n = 4 
[17.4%]), and Staphylococcus aureus (n = 2 [8.7%]). Among the 
15 deaths with “infections” as the underlying CoD, 5 (33.3%) 
were due to GBS (Table 3). Furthermore, 8 of these 15 cases died 
directly from the initial infection, and 4 died from a subsequent 
hospital-acquired infection (Figure 1).
In 67 (74.4%) deaths with “infections” as either an underlying 
or immediate CoD (n = 90), the infections were hospital-acquired, 
including 5 with concurrently diagnosed sepsis and pneumonia 
caused by different pathogens in the blood and lung as the im-
mediate CoD (Table 3). Hospital-acquired infections were more 
common in LND (64/106 [60.4%]) than END (3/47 [6.4%]) 
(P < .001; Table 2). The most common hospital-acquired patho-
gens were Acinetobacter baumannii (52.2%), Klebsiella pneumoniae 
(22.4%), S.  aureus (20.9%), E.  coli (6.0%), Enterococcus faecium 
(7.5%), and Candida parapsilosis (4.5%) (Table 3).
Underlying and Specific Immediate Cause of Death
Total  
(N = 153)
Early Neonatal Death 
(n = 47)
Late Neonatal Death  
(n = 106) P Valuea
Neonatal death of unspecified cause (N11)a n = 1 (0.7) n = 0 (0.0) n = 1 (0.9) .99
 Shock 1 (100) 0 (0.0) 1 (100)  
Data are presented as No. (%) unless otherwise indicated. Causes of death (CoD) are according to the World Health Organization International Classification of Diseases, Tenth Revision 
(ICD-10) application to perinatal mortality. 
aIndicates ICD-10 code categories.
bComparisons of immediate CoD not done due to limited power.
cFour cases had pneumonia as coimmediate CoD and are thus counted under pneumonia. Two of the cases had the same pathogen for sepsis and pneumonia, whereas the other 2 had 
different pathogens causing the sepsis and pneumonia. 
dTwo nosocomial Acinetobacter baumannii meningitis cases had nosocomial pneumonia as coimmediate CoD; 1 was A. baumannii and the other was Klebsiella pneumoniae.
eThis case of birth asphyxia had hyaline membrane disease (HMD) as coimmediate CoD. 
fTwo cases of HMD had other coimmediate CoD. One had persistent fetal circulation and the other had unspecified pneumonia. 
gOne case had HMD and another case had meconium aspiration syndrome as coimmediate CoD to hypoxic ischemic encephalopathy.
hOne case had 2 coimmediate CoD, both congenital malformations: congenital hypoplasia and dysplasia of lung and Potter syndrome.
iSix cases had the same pathogen as the immediate and underlying CoD.
jOne case of pneumocystis pneumonia had rotavirus gastroenteritis as a coimmediate CoD.
kThe case of nosocomial A. baumannii meningitis had nosocomial A. baumannii pneumonia as a coimmediate CoD. 
lOne case of persistent fetal circulation also had nosocomial A. baumannii sepsis as a coimmediate CoD. 
mThis case of nosocomial K. pneumoniae pneumonia also had nosocomial sepsis (Enterobacter cloacae and A. baumannii) as coimmediate CoD.
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The antibiotic resistance profile of bacteria implicated as an 
underlying or immediate CoD is tabulated in Supplementary 
Table 5. Acinetobacter baumannii isolates were generally re-
sistant to all classes of antibiotics, including 100% (46/46) to 
carbapenems and 100% (45/45) to piperacillin/tazobactam, 
but sensitive to colistin. Similarly, K. pneumoniae isolates were 
generally resistant to most classes of antibiotics, including 
73.9% (17/23) to cefotaxime, but sensitive to carbapenems and 
amikacin (4.0% [1/25]) resistance); albeit generally resistant to 
other aminoglycosides. One hundred percent (15/15) of S. au-
reus isolates were methicillin resistant.
DISCUSSION
This study demonstrated that MITS, coupled with medical re-
cord review, is a robust method to determine the underlying and 
highly specific immediate causes of deaths occurring in  neo-
nates in a LMIC setting. The acceptability of MITS in our study, 
where two-thirds of bereaved parents agreed to study partici-
pation, was similar to the hypothetical acceptability thereof in 
a multicenter study [8] and affirms its ability to bridge the data 
gap arising from inter alia cultural and religious barriers in un-
dertaking CDA in LMICs [8].
n = 4
n = 1
n = 4 n = 4
n = 4
n = 7
n = 2 n = 2 n = 2 n = 2
n = 2
n = 1 n = 1
n = 3
n = 26
n = 2 n = 4 n = 1
n = 14
n = 9
n = 1 n = 1 n = 1
n = 4
n = 21
0%
10%
20%
30%
40%
50%
60%
70%
80%
Co
m
m
un
ity
-a
cq
ui
re
d
se
ps
is
No
so
co
m
ia
l-a
cq
ui
re
d
se
ps
is
Co
m
m
un
ity
-a
cq
ui
re
d
pn
eu
m
on
ia
No
so
co
m
ia
l-a
cq
ui
re
d
pn
eu
m
on
ia
No
so
co
m
ia
l-a
cq
ui
re
d
m
en
in
gi
s
Hy
po
xic
 e
nc
ep
ha
lo
pa
th
y
Hy
al
in
e 
m
em
br
an
e
di
se
as
e O
th
er
LBW/Prematurity complicaons
n = 16
0%
10%
20%
30%
40%
50%
60%
70%
80%
Co
m
m
un
ity
-a
cq
ui
re
d
se
ps
is
No
so
co
m
ia
l-a
cq
ui
re
d
pn
eu
m
on
ia
In
tr
au
te
rin
e 
hy
po
xi
a
Hy
po
xi
c e
nc
ep
ha
lo
pa
th
y
Ot
he
r
Complicaons of intrapartum  events 
0%
10%
20%
30%
40%
50%
60%
70%
80%
Co
m
m
un
ity
-a
cq
ui
re
d
se
ps
is
No
so
co
m
ia
l-a
cq
ui
re
d
se
ps
is
Co
m
m
un
ity
-a
cq
ui
re
d
pn
eu
m
on
ia
No
so
co
m
ia
l-a
cq
ui
re
d
pn
eu
m
on
ia
Co
m
m
un
ity
-a
cq
ui
re
d
m
en
in
gi
s
In
tr
au
te
rin
e 
hy
po
xi
a
Ot
he
r
Infecon
Underlying cause of death categories
0%
10%
20%
30%
40%
50%
60%
70%
80%
sispes
deriuqca-ytinu
m
moC
sispes
deriuqca-lai
mocosoN
Co
m
m
un
ity
-a
cq
ui
re
d
pn
eu
m
on
ia
No
so
co
m
ia
l-a
cq
ui
re
d
pn
eu
m
on
ia
Co
ng
en
ita
l m
al
fo
rm
a
on
s
Ot
he
r
Congenital malformaons/ chromosomal 
disorder
Immediate cause of death
Immediate cause of death
Underlying cause of death categories
Figure 1. Immediate causes of death by leading underlying cause of death category in all neonates. “Other” includes persistent fetal circulation, intraventricular hem-
orrhage, birth asphyxia, kernicterus, necrotizing enterocolitis, pulmonary mucormycosis, vascular disorders of intestines, subarachnoid hemorrhage, acute kidney failure, 
pneumothorax, pulmonary hemorrhage, shock, and acquired hydrocephalus. Abbreviation: LBW, low birth weight.
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The data generated from this pilot study to the CHAMPS pro-
gram provide proof of principle that MITS is feasible with in-
formative findings. These findings set the stage for multicenter 
mortality surveillance, which could be instrumental in priori-
tizing strategies and interventions to reduce neonatal mortality 
[6]. This could include identifying and addressing diseases, 
which could be prevented, or treated in neonatal deaths attrib-
uted to underlying conditions such as “LBW/preterm compli-
cations,” which need not be life-threatening. An overwhelming 
finding from our study was the dominant but underempha-
sized role of hospital-acquired infections to in-facility neonatal 
deaths, especially in LNDs (60.4%). Notably, the dominant 
pathogen, A.  baumannii, was resistant to all classes of anti-
biotics except for colistin, which is not licensed for use in neo-
nates in South Africa. The observations on the contribution of 
hospital-acquired infections as a cause of neonatal deaths in 
this study have underpinned a reevaluation and introduction 
of strategies aimed to improve infection control practices at 
CHBAH, the success of which will be evaluated through the on-
going CHAMPS program in Soweto.
Our study also demonstrates the need to evaluate cause-
specific mortality fraction beyond analysis of the underlying 
CoD as is currently the focus of estimates on causes of neo-
natal deaths [2]. Notably, infections that could potentially be 
prevented or treated were the immediate CoD among 70.4% 
and 45.0% of cases with “LBW/prematurity complications” and 
“congenital abnormalities,” respectively, which were among 
the 3 leading underlying CoD. Furthermore, 79.8% of LNDs 
were infection related—also almost exclusively due to hospital-
acquired infections. In contrast, among ENDs with “LBW/pre-
maturity complications” as an underlying CoD, the immediate 
CoD were predominantly due to histologically confirmed hya-
line membrane disease (50%) and other common complications 
of prematurity.
The value of postmortem bacterial culture in attributing a 
casual association to death is controversial due to multiple po-
tential sources of sample contamination, including postmortem 
aspiration of gastrointestinal and upper airway colonizing bac-
teria, or translocation of enteric bacteria into the bloodstream. 
Nevertheless, implicating bacterial infection as the CoD in this 
study was done only after review of each individual case, and 
considering multiple corroborating lines of evidence available 
for each death. For example, pneumonia-attributed deaths were 
corroborated by lung pathology, showing histological evidence 
of pneumonia, coupled with immunohistochemical evidence of 
infection, in addition to PCR detection and/or culture positivity. 
Also, sepsis was typically diagnosed based on culture and/or 
PCR positivity from >1 site (postmortem) if premortem culture 
was negative or PCR positivity from at least 1 site (postmortem) 
coupled with premortem culture showing the same organism, 
and often with histopathological evidence of sepsis from mul-
tiple organs. Furthermore, in support that MITS sampling for 
identifying infectious-related deaths was not attributable to 
environmental contamination was the difference in frequency 
of identification and spectrum of pathogens implicated as the 
cause of infection between END and LND cases. The domi-
nant bacteria implicated as causing infection-related END were 
those commonly colonizing the maternal rectovaginal tract 
in our setting [12], which could cause invasive disease in the 
newborn following bacterial infection in utero or during birth. 
Nevertheless, the possibility of postmortem contamination by 
these organisms cannot be excluded.
Although the burden of hospital infections and spectra of im-
plicated pathogens might be site-specific [13], the importance 
of hospital infection as a cause of neonatal mortality has also 
been observed in other LMIC settings on antemortem sam-
pling. In Zambia, high case fatality ratios (29%–47%) were re-
ported in hospitalized neonates with suspected sepsis, among 
whom extended-spectrum β-lactamase K. pneumoniae was the 
dominant (75%) pathogen and primarily hospital-acquired 
[14]. Gram-negative bacteria, particularly Acinetobacter spe-
cies (22%) and Klebsiella species (17%), were also the dominant 
cause of neonatal sepsis in India, with high rates of multidrug re-
sistance observed for Acinetobacter species (82%) and Klebsiella 
species (54%). Notably, one-quarter of neonatal deaths in the 
Indian study were attributable to sepsis based on antemortem 
sampling [15], which could be an underestimate due to low-
to-moderate sensitivity of blood culture in detecting bacterial 
infections [13].
The proportional distribution of underlying CoD in neo-
nates in our study differed from that estimated nationally for 
South Africa in 2015 [2]. These differences included a higher 
percentage of deaths in our study being attributed to “LBW/
prematurity complications” (52.9% vs 35%) and “congen-
ital abnormalities” (9.2% vs 3.1%), and a lower percentage to 
“complications of intrapartum events” (15.0% vs 21.4%), and 
“infections” (9.8% vs 20.6%). The national estimates are, how-
ever, based on passive reporting from vital registration data-
bases and limited verbal autopsy reports, which could explain 
the discordance. A  limitation of our study, and the compar-
ison to the national estimates, was that it was a single facility-
based study; hence, our findings may not be generalizable to 
the broader community or other settings with different levels 
of healthcare access. Although a strength of the study setting 
was the presence of a single public referral hospital in Soweto, 
we could have missed community deaths not brought to the 
hospital.
Another study limitation was that the commercially avail-
able multiplex PCR assay was not customized for this study, 
including lacking targets to evaluate for the most common bac-
teria (ie, A.  baumannii and K.  pneumoniae) causing hospital-
acquired infections.
Notably, the distribution of timing of neonatal deaths rep-
resented in our study differs from the global trend, where 
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approximately 50% of neonatal deaths are estimated to occur 
within 72 hours of birth [16], compared to 30.7% of cases 
sampled in our study. This could be explained by the majority 
(>95%) of deliveries in our setting occurring within healthcare 
facilities, as well as reasonable access to curative healthcare in-
cluding intensive care facilities, and hence a better chance of 
neonatal survival within 72 hours of birth. Furthermore, the ex-
clusion of newborns with birth weight of <750 g, who are highly 
likely to die within a few hours of birth in the absence of full 
access to intensive care interventions, including in our setting, 
might have also contributed to these differences.
The aspiration of providing “universal healthcare” as envi-
sioned in the United Nations Sustainable Development Goal 3.8 
[17], could possibly lead to epidemiological shifts in the timing 
of neonatal deaths globally. This includes potentially a greater 
role of hospital-acquired infections as an immediate cause of 
neonatal deaths, as the number of deliveries attended by skilled 
healthcare workers has steadily increased from 60% in 2000 to 
80% by 2015 globally [18], and many babies born preterm are 
now more likely to stay in hospital after delivery. Consequently, 
greater focus may be required now to mitigate the risk of hos-
pital infections, particularly in prematurely born neonates, as 
alluded to in our study.
In conclusion, in this proof-of-concept study to the CHAMPS 
program, we demonstrate the potential role of MITS interpreted 
with other clinical information in addressing the knowledge gap 
on causes of neonatal mortality. Future surveillance using MITS 
in the multicenter CHAMPS program will contribute to inform 
decision making in the prioritization of interventions and re-
search that need to be undertaken to reduce neonatal deaths.
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